Malaria Antibody ELISA Insufficiently Sensitive for Blood Donor Screening

Mertens, Gerhard; Vervoort, T.; Heylen, Sandra; Muylle, L.

doi:10.1046/j.1423-0410.1999.77402371.x

Cited by 11 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ltd., Brookvale, NSW, Australia) claims detection of antibodies against the four principal Plasmodium species that cause malaria in humans with a sensitivity of 94% versus IFA (per package insert). However, Mertens et al (32) indicated poor sensitivity of the assay compared to IFA for P. falciparum (64%) and non-P. falciparum (0 to 33%) malaria antibody detection. Evaluation of the assay by She et al (44) showed an inability of the assay to detect antibodies in some individuals who gave positive results for P. ovale or P. malariae antibodies by IFA.…”

Section: Discussionmentioning

confidence: 99%

“…Commercially available ELISAs have been developed that use recombinant antigens or P. falciparum whole-organism lysates for detection of immunoglobulins (IgG and/or IgM, IgA) in human serum or plasma (Lab 21 Healthcare Laboratories, United Kingdom; Cellabs, Australia; DiaMed AG, Switzerland; LG Chemical Inc., Iksan, South Korea; Green Cross, Inc., Youngin, South Korea [Genedia Malaria Ab Rapid]; and Standard Diagnostics, Suwon, South Korea). These assays are typically easier to perform and exhibit higher throughput and better sensitivity and specificity than IFA (25,42,47), though this is not always the case (32). Some ELISAs may be better than others for detection of antibodies against all four Plasmodium species that cause malaria in humans (44).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Detection ofPlasmodium falciparum,P. vivax,P. ovale, andP. malariaeMerozoite Surface Protein 1-p19 Antibodies in Human Malaria Patients and Experimentally Infected Nonhuman Primates

Muerhoff

Birkenmeyer

Coffey

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Approximately 3.2 billion people live in areas where malaria is endemic, and WHO estimates that 350 to 500 million malaria cases occur each year worldwide. This high prevalence, and the high frequency of international travel, creates significant risk for the exportation of malaria to countries where malaria is not endemic and for the introduction of malaria organisms into the blood supply. Since all four human infectious Plasmodium species have been transmitted by blood transfusion, we sought to develop an enzyme-linked immunosorbent assay (ELISA) capable of detecting antibodies elicited by infection with any of these species. The merozoite surface protein 1 (MSP1), a P. falciparum and P. vivax vaccine candidate with a well-characterized immune response, was selected for use in the assay. The MSP1 genes from P. ovale and P. malariae The commercial ELISA detected all malaria patients with P. falciparum or P. vivax infections, as did the corresponding species-specific p19 ELISAs. However, the commercial ELISA detected antibodies in 0/2 and 5/8 individuals with P. malariae and P. ovale infections, respectively, while the p19 assays detected 100% of individuals with confirmed P. malariae or P. ovale infections. In experimentally infected nonhuman primates, the use of MSP1-p19 antigens from all four species resulted in the detection of antibodies within 2 to 10 weeks postinfection. Use of MSP1-p19 antigens from all four Plasmodium species in a single immunoassay would provide significantly improved efficacy compared to existing tests.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Detection ofPlasmodium falciparum,P. vivax,P. ovale, andP. malariaeMerozoite Surface Protein 1-p19 Antibodies in Human Malaria Patients and Experimentally Infected Nonhuman Primates

Muerhoff

Birkenmeyer

Coffey

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…First generation ELISA kits, based exclusively on P. falciparum antigens, showed a poor sensitivity for P. vivax infection [22-24]. The relatively poor sensitivity of other ELISA methods could be due to the use of soluble P. falciparum antigens without P. vivax antigens [13].…”

Section: Discussionmentioning

confidence: 99%

A new ELISA kit which uses a combination of Plasmodium falciparum extract and recombinant Plasmodium vivax antigens as an alternative to IFAT for detection of malaria antibodies

Doderer

Heschung

Guntz

et al. 2007

Malar J

View full text Add to dashboard Cite

Background: The methods most commonly used to measure malarial antibody titres are the Indirect Fluorescence Antibody Test (IFAT), regarded as the gold standard, and the Enzyme-Linked ImmunoSorbent Assay (ELISA). The objective here was to assess the diagnostic performance, i.e. the sensitivity and specificity, of a new malaria antibody ELISA kit in comparison to IFAT. This new ELISA kit, the ELISA malaria antibody test (DiaMed), uses a combination of crude soluble Plasmodium falciparum extract and recombinant Plasmodium vivax antigens.

show abstract

“…The negative impact of a temporary deferral of donors on the return of donors is not negated. While there are several reports of the use of the malaria antibody ELISA to screen blood donors, 26‐28 the sensitivity of the ELISA is not high, 28 and it has been suggested that both a malaria antibody ELISA and antigen‐based technique be used to screen blood donors 26,27 . One technique for screening donors would be preferable.…”

Section: Discussionmentioning

confidence: 99%